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Effects of erythropoietin on left ventricular hypertrophy in
adults with severe chronic renal failure and hemoglobin
<10 g/dL.
Background. Left ventricular hypertrophy (LVH) frequently
complicates chronic renal insufficiency. Anemia is also common
in these patients and may contribute to LVH.
Methods. We conducted an open-label interventional trial to
evaluate the effect of recombinant erythropoietin (rhEPO) on
left ventricular mass index (LVMI) in anemic patients with renal
insufficiency. Adults with creatinine clearance 10 to 30 mL/min
(nondiabetics) or 20 to 40 mL/min (diabetics) were recruited,
and rhEPO was given to those with anemia (hemoglobin level
<10 g/dL). Baseline and 6-month LVMI and LVH (LVMI
>130 g/m2 in men and >100 g/m2 in women), hemoglobin levels,
creatinine clearance, blood pressure, medications, and medical
history were obtained. Forty anemic and 61 nonanemic control
subjects were enrolled.
Results. Overall, the prevalence of LVH was 68.3% (95%
CI 58.3-77.2), and entry hemoglobin level was the only signif-
icant predictor of baseline LVH (adjusted OR 0.69 per g/dL
increase in hemoglobin, 95% CI 0.50-0.94). After 6 months,
LVMI decreased in anemic patients receiving rhEPO (142 ± 56
vs. 157 ± 56 g/m2) (P = 0.007), with an increase in hemoglobin
(11.3 ± 1.9 vs. 9.1 ± 0.7 g/dL) (P = 0.001). There were no
changes in LVMI or hemoglobin level among controls. After
adjusting for confounders and change in hemoglobin, receipt
of rhEPO was associated with a significant reduction in LVMI
(P = 0.01).
Conclusion. Treatment with rhEPO was not independently
associated with significant changes in blood pressure or renal
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function. LVH is a common finding in chronic renal insufficiency
and is associated with lower hemoglobin levels. Treatment with
rhEPO may decrease LVH in patients with severe renal insuf-
ficiency and anemia.
The incidence and prevalence of chronic kidney dis-
ease is increasing in the United States [1–3] and car-
diovascular disease continues to be the leading cause of
morbidity and mortality in patients with end-stage renal
disease (ESRD) [3–6] as well as those with severe chronic
renal insufficiency not yet requiring dialysis [7–11]. Car-
diovascular structural and functional abnormalities, es-
pecially left ventricular hypertrophy (LVH), frequently
occur in patients with ESRD who are beginning mainte-
nance dialysis [12, 13], with only 16% of these patients
having normal echocardiographic findings at dialysis ini-
tiation [12]. LVH has been shown to be an independent
risk factor for cardiovascular mortality in patients with
ESRD [12, 14]. In patients with ESRD and a left ven-
tricular mass index (LVMI) >125 g/m2, 5-year survival is
slightly more than 20% while among patients with ESRD
and an LVMI <125 g/m2, 5-year survival is 50% [14].
The presence of LVH is also an important risk factor
for the development of chronic heart failure on main-
tenance hemodialysis [15]. The impact of chronic heart
failure on survival in ESRD patients on renal replace-
ment therapy is striking, as the presence of heart failure is
associated with a higher adjusted risk of death compared
with having known coronary heart disease in new ESRD
patients [16]. There is now a greater appreciation that
LVH occurs early in the course of kidney failure, com-
monly affecting patients with chronic renal insufficiency,
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and reduced hemoglobin level has been identified as an
important risk factor for its development [12, 13, 17, 18].
Therefore, successful therapies that can reduce the de-
velopment and progression of LVH among patients with
advanced chronic renal insufficiency may help to reduce
the associated high rates of cardiac morbidity and mor-
tality in this population and is an emerging therapeutic
target.
Correction of anemia with recombinant erythropoietin
(rhEPO) has been associated with improvement of LVH
in patients with ESRD receiving maintenance dialysis
[19, 20], but relatively little is known about its effects
in patients with advanced chronic renal insufficiency not
yet requiring renal replacement therapy. We conducted
a prospective trial to evaluate the impact of rhEPO on
left ventricular echocardiographic parameters in patients
with severe chronic renal insufficiency complicated by
anemia. We hypothesized that receipt of rhEPO would
be associated with an improvement in LVH in anemic
patients with severe renal insufficiency.
METHODS
Study sample
From 1997 to 1999, members of the Spanish Group
for the Study of Left Ventricular Hypertrophy in Pre-
dialysis Patients recruited patients from a consortium of
university and community hospitals in Spain who were
age 18 years or older; who had a Cockcroft-Gault crea-
tinine clearance [21] of 10 to 30 mL/min in nodiabetics
and 20 to 40 mL/min in diabetics (approximately stage 4
chronic kidney disease); [22] and who had not previously
received rhEPO treatment. Kidney function was assessed
on two separate occasions during consecutive months
prior to enrollment into the study, and the Cockcroft-
Gault–calculated creatinine clearance from these two
measurements was averaged and this was used as the
baseline creatinine clearance for the study. We used
Cockcroft-Gault creatinine clearance to estimate under-
lying glomerular filtration rate (GFR) consistent with op-
tions recommended in recent national guidelines [22].
We excluded patients who had a functional vascular ac-
cess, prior acute myocardial infarction, known valvular
heart disease, significant cardiac arrhythmia, congestive
heart failure, systemic conditions with potential myocar-
dial involvement (e.g., amyloidosis, systemic lupus, or vas-
culitis), or uncontrolled hypertension. The demographic
characteristics and baseline level of comorbidity of the
patients enrolled are reflective of the general ESRD pop-
ulation in Spain [23].
Written informed consent was obtained for all patients
and participating centers’ institutional review boards ap-
proved the study.
Study design and follow-up
We conducted a prospective, open-label trial of the ef-
fects of rhEPO on LVH based on the presence or ab-
sence of anemia, defined as a hemoglobin level <10 g/dL
at entry. At study entry, hemoglobin levels (g/dL) and
LVMI by standard echocardiographic methods were as-
sessed [24, 25]. Only eligible patients found to be anemic
were treated with subcutaneous rhEPO, with the dose
adjusted to achieve a hemoglobin level of 12 g/dL, as the
study’s steering committee and participating institutions’
institutional review boards concluded that it was unethi-
cal to conduct a placebo-controlled study based on exist-
ing clinical practice guidelines. The mean dose of rhEPO
used was 4100 ± 325 U/week. During the study, patients
receiving rhEPO also received oral iron supplements to
maintain serum ferritin levels of ≥150 lg/L and a trans-
ferrin saturation index ≥20%, intravenous iron was not
used. None of the patients developed functional iron de-
ficiency (ferritin <150 mcg/L or transferring saturation
index of <20%). Follow-up was discontinued if patients
received arteriovenous vascular access, initiated dialysis,
died, or dropped out of the study, but no patients met
these criteria.
The original planned duration of follow-up for the
study was 12 months, with an interim analysis after
6 months of follow-up. As per the original protocol de-
veloped by the study steering committee and required
by the institutional review boards of participating institu-
tions, study was terminated based on findings of a positive
effect associated with receipt of rhEPO at the 6-month
follow-up evaluation.
Clinical and biochemical characteristics
At study entry, we collected information on relevant
medical history, including diabetes mellitus, dyslipidemia,
and cigarette (never, current, or former) and alcohol
use (yes or no), and presumed etiology of renal dis-
ease (diabetes mellitus, glomerulonephritis, polycystic
kidney disease, nephrosclerosis, interstitial disease, ren-
ovascular disease, other etiology, or undetermined). We
also obtained data on targeted medical therapies, includ-
ing angiotensin-converting enzyme (ACE) inhibitors, an-
giotensin II receptor blockers, diuretics, beta blockers,
calcium channel blockers, alpha blockers, vasodilators,
and other antihypertensive agents.
Baseline and 6-month measures of resting blood pres-
sure, heart rate, and body mass index (kg/m2) were
obtained using standard methods. Local laboratories
were used to measure hemoglobin level, Cockcroft-
Gault creatinine clearance (mL/min) based on ambu-
latory serum creatinine concentrations, serum calcium
and phosphorous, plasma parathyroid hormone level,
serum albumin, and plasma lipoprotein levels [total
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cholesterol, high-density lipoprotein (HDL) cholesterol,
triglycerides, and low-density lipoprotein (LDL) calcu-
lated using the Friedewald equation [26]].
Of note, there were no differences between the groups
with regard to nephrology care before entering the study
or the subsequent number of medical visits during the
study. All patients were seen in the clinic by the site in-
vestigator and a study coordinator at each visit.
Baseline characteristics
A total of 162 patients were assessed for possible eligi-
bility, and 140 patients agreed to be screened. Of these,
101 patients met enrollment criteria and agreed to par-
ticipate, with 50% being men and a mean age of 60.5 ±
14.4 years (range 21 to 85 years). Forty patients (40.0%)
met criteria for anemia (hemoglobin <10 g/dL) at en-
try. At baseline, the only significant differences in clinical
or treatment characteristics among anemic and nonane-
mic subjects were slightly lower creatinine clearance and
higher serum phosphorus level in anemic subjects (Ta-
bles 1 and 2).
Outcome variables
The primary outcome of interest was within-person
change in LVMI between study entry and the end of
follow-up.
Baseline and 6-month follow-up transthoracic echocar-
diographic studies were performed by the same cardiol-
ogist, in a blinded fashion, at each participating center
using standardized protocols. A separate echocardio-
graphic cardiologist blinded to group and treatment
status independently reviewed and evaluated all echocar-
diograms. Using standard methods, readings were taken
in the lateral decubitus position using M-mode and
Doppler techniques, including measurement of left ven-
tricular ejection fraction and fractional shortening, as well
as the waves from protodiastolic filling (E wave) and tele-
diastolic atrial contraction filling (A wave) to calculate
E-to-A ratio. Inter-ventricular septal thickness was mea-
sured, excluding the thickness of the right and left en-
docardium, along with left ventricular posterior wall
thickness, excluding the thickness of the endocardium
and epicardium-pericardium.
Left ventricular mass was calculated using the Dev-
ereux formula corrected for body surface area to deter-
mine LVMI [24]. A secondary outcome was the presence
of echocardiographic LVH was based on the Framing-
ham Heart Study criteria of LVMI >130 g/m2 for men
and >100 g/m2 for women [25].
From previous quality control measures of the echocar-
diography laboratories used in this study, the intrarater
variability for the cardiologists reading the echocardio-
grams in the study has been less than 5%. All echocar-
diograms were re-reviewed by a single cardiologist at a
centralized location; and in the case of any discrepan-
cies in the reviews by greater than 10%, the studies were
submitted to a third cardiologist without any formal as-
sociation with the study for review.
Statistical approach
Continuous variables are presented as means with
standard deviations or medians, with comparisons be-
tween groups using Student t test or Mann-Whitney rank-
sum test. Categorical variables were compared between
groups using Pearson’s chi-squared test.
We first performed multivariable logistic regression to
identify independent correlates of having LVH at study
entry among the entire cohort, with candidate variables
including characteristics previously reported to be asso-
ciated with LVH as well as those variables associated with
LVH on bivariate analyses with a P < 0.05.
We performed analyses for within-person changes dur-
ing follow-up to compare the change in LVMI among
patients who received rhEPO versus that among control
subjects, after adjustment for known correlates of LVH
and any baseline differences between groups on bivariate
analyses with a P < 0.05, except for 6-month hemoglobin
or change in hemoglobin during follow-up which were
hypothesized to potentially be causally related to any ob-
served effect of rhEPO on left ventricular parameters.
In the final model, we included 6-month hemoglobin or
change in hemoglobin to assess whether this mediated
the observed results by examining the change in the b
coefficient. Finally, we also examined the association be-
tween rhEPO therapy and change in creatinine clearance
using multivariable linear regression.
We also conducted comparisons between the treatment
and control groups in the unadjusted rates of LVH at
study entry and at the end of follow-up.
A two-tailed P value < 0.05 was considered statistically
significant. All analyses were performed using Stata 8.2
(Stata Corporation, College Station, TX, USA).
Role of the funding source
The funding source provided financial support and
study drug. However, the study design and all analyses
were independently developed, conducted, interpreted,
and reported by the study investigators.
RESULTS
Baseline LVH in anemic vs. nonanemic subjects
Overall, 68.3% (95% CI 58.3 to 77.2) of all subjects
met criteria for echocardiographic LVH at study entry.
The mean LVMI was significantly higher in anemic com-
pared with nonanemic subjects; similarly, the prevalence
of LVH was substantially higher among anemic compared
with nonanemic subjects (87.5% vs. 55.7%, respectively)
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Table 1. Baseline characteristics of subjects with chronic renal insufficiency stratified by baseline anemia status
Anemic subjects Nonanemic Subjects
(hemoglobin <10 g/dL) (hemoglobin ≥10 g/dL)
Characteristic (N = 40) (N = 61) P value
Mean (SD) age years 59.5 (15.8) 61.1 (13.6) 0.58
Women% 60.0 44.3 0.12
Mean (SD) hemoglobin g/dL 9.1 (0.7) 12.1 (1.3) <0.001
Mean (SD) creatinine clearance mL/min 17.3 (5.8) 21.7 (7.0) 0.002
Tobacco use% 0.93
Never 75.0 77.0
Current 7.5 8.2
Former 17.5 14.8
Alcohol use% 5.0 1.6 0.33
Diabetes mellitus% 30.0 19.7 0.23
Dyslipidemia% 27.5 27.9 0.97
Presumed etiology of renal insufficiency % 0.46
Diabetes mellitus 25.0 18.0
Glomeruloneprhitis 15.0 24.6
Polycystic kidney disease 10.0 16.4
Nephrosclerosis 10.0 14.8
Interstitial disease 2.5 4.9
Renovascular disease 5.0 1.6
Undetermined 7.5 8.2
Other etiology 25.0 11.5
Medication %
Angiotensin-converting enzyme inhibitor 45.0 50.8 0.56
Angiotensin receptor blocker 8.1 7.1 0.86
Diuretic 18.9 32.1 0.16
Beta blocker 2.7 14.3 0.06
Calcium channel blocker 57.5 47.5 0.33
Alpha blocker 21.6 10.7 0.15
Vasodilator 5.4 3.6 0.67
Other antihypertensive 8.1 8.9 0.89
Mean (SD) systolic blood pressure mm Hg 148 (21) 146 (19) 0.56
Mean (SD) diastolic blood pressure mm Hg 82 (11) 83 (9) 0.60
Mean (SD) heart rate beats/min 79 (10) 77 (13) 0.32
Mean (SD) body mass index kg/m2 26.1 (3.3) 27.5 (4.5) 0.10
Table 2. Baseline laboratory and echocardiographic measures stratified by baseline anemia status
Anemic subjects Nonanemic subjects
(hemoglobin <10 g/dL) (hemoglobin ≥10 g/dL)
Characteristic (N = 40) (N = 61) P value
Selected laboratory measures
Mean (SD) serum calcium mg/dLa 9.0 (0.9) 9.0 (1.7) 0.85
Mean (SD) serum phosphorus mg/dLa 5.0 (0.8) 4.2 (0.7) <0.001
Median (interquartile range) plasma parathyroid hormone pg/mLb 180 (93–289) 112 (65–250) 0.19
Mean (SD) serum albumin g/Lc 4.2 (0.6) 4.4 (0.7) 0.08
Mean (SD) total cholesterol mg/dLd 200 (41) 216 (44) 0.10
Mean (SD) high-density lipoprotein cholesterol mg/dLe 42 (10) 49 (17) 0.04
Mean (SD) low-density lipoprotein cholesterol mg/dLf 159 (40) 165 (48) 0.63
Mean (SD) triglycerides mg/dLg 134 (59) 148 (65) 0.30
Baseline echocardiographic measures, mean (SD)
Left ventricular mass index g/m2 157.0 (55.7) 131.2 (42.7) 0.01
Interventricular septal thickness mm 11.6 (2.4) 10.7 (2.8) 0.08
Left ventricular posterior wall thickness mm 10.8 (2.1) 10.5 (2.4) 0.57
Left ventricular ejection fraction% 60.7 (10.2) 60.4 (11.0) 0.89
Left ventricular fractional shortening% 37.0 (7.8) 36.8 (8.5) 0.91
E-to-A ratio 0.93 (0.35) 0.90 (0.41) 0.72
E to A ratio is measurement of left ventricular ejection fraction and fractional shortening, as well as the waves from portodiastolic filling (E wave) and telediastolic
atrial contraction filling (A wave).
aIn 34 anemic and 56 nonanemic patients with available data.
bIn 32 anemic and 52 nonanemic patients with available data.
cIn 37 anemic and 58 nonanemic patients with available data.
dIn 35 anemic and 56 nonanemic patients with available data.
eIn 30 anemic and 50 nonanemic patients with available data.
fIn 29 anemic and 50 nonanemic patients with available data.
gIn 34 anemic and 55 nonanemic patients with available data.
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Fig. 1. Median change in left ventricular mass index over a 6-month
follow-up period comparing anemic patients who received recombinant
human erythropoietin (r-HuEPO) with nonanemic control subjects.
Error bars represent interquartile ranges.
(P = 0.001). There were no other significant differences
in other echocardiographic parameters between groups
at baseline (Table 2).
Correlates of LVH
In the entire sample, only hemoglobin level was an in-
dependent predictor of LVH at baseline. After adjust-
ment for potential confounders including age, gender,
etiology of renal disease, diabetes mellitus, tobacco use,
body mass index, baseline systolic and diastolic blood
pressure, and use of ACE inhibitors or beta blockers,
a higher hemoglobin level was associated with a lower
likelihood of having LVH (adjusted OR 0.69 per g/dL in-
crease in hemoglobin, 95% CI 0.50 to 0.94). Of note, at
baseline and at the end of follow-up, there were no signif-
icant differences among those subjects with documented
LVH in the proportion of the eccentric versus concentric
LVH in either group (data not shown).
EPO and changes in LVMI
At 6 months, hemoglobin level was increased com-
pared with baseline levels in subjects receiving rhEPO
(11.3 ± 1.9 vs. 9.1 ± 0.7 g/dL, respectively) (P < 0.001),
but not in control subjects (11.9 ± 1.5 vs. 12.1 ± 1.3 g/dL,
respectively) (P = 0.06).
Among patients treated with rhEPO, mean LVMI was
significantly lower at 6 months compared with base-
line (142.0 ± 55.7 vs. 157.0 ± 55.7 g/m2, respectively)
(P = 0.007). However, there was no significant change in
mean LVMI at 6-month follow-up compared with base-
line among nonanemic controls (137.1 ± 50.6 vs. 131.2 ±
42.7 g/m2, respectively) (P = 0.23) (Fig. 1).
At 6 months of follow-up, the prevalence of echocar-
diographic LVH was lower but not significantly differ-
ent than at baseline among anemic subjects receiving
rhEPO (75.0% vs. 87.5%, respectively) (P = 0.31), while
the prevalence of LVH was significantly higher among
nonanemic controls at the end of follow-up compared
with baseline (59.0% vs. 55.7%, respectively) (P = 0.02).
Interestingly, in comparing across groups, the prevalence
of LVH was not significantly different at the end of follow-
up (75.0% in anemic subjects vs. 59.0% in controls) (P =
0.10).
We found no significant differences at 6 months com-
pared with baseline for left ventricular ejection fraction
in anemic patients treated with rhEPO (61.2% ± 8.6% vs.
60.7% ± 10.2%, respectively) (P = 0.74) or control sub-
jects (61.6% ± 10.7% vs. 60.4% ± 11.0%, respectively)
(P = 0.39). Of note, there were no significant changes at
6 months in E-to-A ratios, interventricular septal thick-
ness, or left ventricular posterior wall thickness in either
group (data not shown).
After adjustment for potential differences in age, gen-
der, baseline hemoglobin level, baseline LVMI, diabetes
status, etiology of renal disease, body mass index, ACE
inhibitor use, beta blocker use, baseline and change in sys-
tolic and diastolic blood pressure, baseline and change in
creatinine clearance, and baseline and change in left ven-
tricular ejection fraction, we found that receipt of rhEPO
was associated with a significant decrease in LVMI (b =
−33.8, P = 0.01) over the 6-month follow-up. Finally, nei-
ther adding in the final hemoglobin level at 6 months or
the 6-month change in hemoglobin level to the model
significantly affected the observed association between
rhEPO and LVMI.
EPO, change in blood pressure, renal function, and lab-
oratory values
There were no significant changes at 6-month follow-
up compared with baseline in mean systolic blood pres-
sure (146 ± 18 vs. 148 ± 21 mm Hg, respectively)
(P = 0.54) or diastolic blood pressure (81 ± 9 vs. 82 ±
11 mm Hg, respectively) (P = 0.85) in anemic subjects
who received rhEPO. Similarly, there were no signifi-
cant changes 6 months compared with baseline in systolic
blood pressure (144 ± 15 vs. 146 ± 19 mm Hg, respec-
tively) (P = 0.46) or diastolic blood pressure (82 ± 11
vs. 83 ± 9 mm Hg, respectively) (P = 0.70) in control
subjects.
The unadjusted rate of progression of renal insuffi-
ciency was greater in treated subjects compared with con-
trol subjects (median change in creatinine clearance −3.4
vs. −1.3 mL/min, respectively) (P = 0.005), but rhEPO
was not significantly associated with change in renal
function after adjustment for diabetes status, etiology of
renal disease, and baseline creatinine clearance among
subjects. There was no change in medication use or lab-
oratory values at follow-up. No adverse events were
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reported among patients receiving rhEPO during the
study period.
DISCUSSION
Among adults with advanced chronic renal insuf-
ficiency, we found that reduced hemoglobin level is
associated with increased odds of having echocardio-
graphic LVH and administration of rhEPO in anemic
(hemoglobin <10.0 g/dL) patients with severe renal in-
sufficiency reduced LVMI after 6 months of therapy,
even after accounting for the change in hemoglobin level,
compared with untreated non-anemic controls. LVH af-
fected more than two thirds of our sample overall at
baseline, and was substantially more frequent in patients
with hemoglobin <10.0 g/dL (88%) compared with those
with hemoglobin of ≥10 g/dL (56%) at study entry, de-
spite similar levels of renal dysfunction as estimated by
Cockcroft-Gault creatinine clearance. Our study suggests
that short-term treatment with rhEPO in anemic patients
with severe chronic renal insufficiency not yet requiring
dialysis may reduce LVMI, without any clinically signifi-
cant detrimental effects on blood pressure or renal func-
tion during the 6-month follow-up.
Our study is one of the largest interventional studies re-
ported to date to evaluate the impact of rhEPO on LVMI
in patients with chronic renal insufficiency, with lon-
gitudinal comparisons between anemic and nonanemic
subjects with similar degrees of renal dysfunction at en-
try. Our findings support and materially extend results
of two previously published studies evaluating a total of
20 patients with severe renal insufficiency not yet requir-
ing renal replacement therapy that showed a beneficial
effect of rhEPO on LVH [27, 28]. In these studies, mean
decreases in LVMI of 14 g/m2 [27]and 41 g/m2 [28], respec-
tively, were reported at 12-month and at least 6-month
follow-up periods; thus, our finding of a mean decrease in
LVMI of 12 g/m2 after 6 months of rhEPO therapy among
anemic subjects is of the magnitude expected given our
study design. Interestingly, a recent study of patients who
had Cockcroft-Gault–calculated creatinine clearance of
15 to 50 mL/min plus higher entry hemoglobin levels (11
to 13 g/dL for men and 11 to12 g/dL for women) did
not show a significant change in LVMI over 2 years us-
ing epoetin a to maintain hemoglobin levels at either 12
to 13 g/dL or 10 to 11 g/dL, although there appeared
to be a decrease in LVMI in the subgroup with LVH at
study entry [29]. The latter subgroup findings are consis-
tent with our results, although 88% of our anemic sub-
jects had LVH at entry compared with 30% of subjects
in the study by Roger et al [29], suggesting that rhEPO
may be most beneficial in the setting of established LVH.
The lower prevalence of LVH noted by Roger et al com-
pared with our study may have been due to enrollment
of younger patients with more preserved levels of renal
function and higher hemoglobin levels [29]. Other stud-
ies of patients with comparable severity of renal dysfunc-
tion have observed a similar prevalence of LVH [13]. Our
results, taken in conjunction with these previous stud-
ies on the effects of EPO on LVH suggest that patients
who benefit most from EPO therapy are those with lower
hemoglobin levels (<10 g/dL) and those with preexisting
LVH.
Why use of rhEPO would improve left ventricular
parameters is not completely clear, although emerging
evidence provides several possible explanations. In our
study, rhEPO treatment increased hemoglobin by ap-
proximately 2 g/dL as expected, which would augment
oxygen-carrying capacity, assuming no change in cardiac
output. However, we found that the beneficial association
of rhEPO on reducing LVMI persisted after adjustment
for change in hemoglobin level during follow-up. EPO
is increasingly recognized as playing as playing diverse
roles in the cardiovascular system outside of erythro-
poiesis [30–32]. Several direct beneficial effects of rhEPO
have been proposed, including inhibition of myocardial
cell apoptosis and favorable cardiac remodeling [33–
36], phosphatidylinositol 3′-kinase (PI3K)/Akt-mediated
protection of cultured myocytes from hypoxia-induced
apoptosis [37–39], and improved left ventricular function
and decreased apoptosis following ischemia/reperfusion
(I/R) injury in the myocardium [37, 39–42]. EPO does not
appear to act through influencing sympathetic nerve ac-
tivity or cardiopulmonary baroreceptor sensitivity [43].
Our results are consistent with the hypothesis of direct
beneficial effects of EPO on the myocardium, although
the mechanisms for these actions remain unclear.
Use of EPO for normalizing hemoglobin levels has
been reportedly associated with potential adverse effects
on blood pressure as well as serum creatinine levels [44].
During a 6-month treatment period, we found neither sig-
nificant changes in systolic or diastolic blood pressures
nor any changes in the use or type of antihyperten-
sive therapies. In addition, while Cockcroft-Gault cre-
atinine clearance decreased at a faster crude rate among
patients receiving rhEPO compared with controls, this
difference was no longer significant after controlling
for potential confounders. In fact, previous investigators
have suggested that treatment of anemia with erythropoi-
etin in chronic kidney disease may, in fact, be associated
with a slower progression of renal failure [45–47], which
was not observed in our study. In these previous studies
where EPO treatment was associated with a slower pro-
gression of disease, subjects with diabetes mellitus were
either excluded or were enrolled in relatively modest
numbers [45–47]. Our study population included a sig-
nificant number of subjects with diabetes, with the group
having anemia and receiving rhEPO having somewhat
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more diabetics than the control arm, although the dif-
ference was not statistically significant (30.0% vs. 19.7%,
respectively) (P = 0.23). Given the known rapid progres-
sion of diabetic nephropathy, this may have masked pos-
sible beneficial effects of EPO on renal function in our
study. Additionally, as a requirement of the steering com-
mittee and institutional review board in the institution
where the research was conducted, data were analyzed
at an interim 6-month follow-up period and the trial ter-
minated, if a significant benefit were found. In previous
studies demonstrating that EPO appeared to beneficial
on slowing progression of renal disease, this effect was
noted at 12 to 36 months of follow-up [45–47].
As an open-label, nonrandomized trial, we cannot
completely exclude effects of residual confounding or
cointervention in evaluating the impact of rhEPO. Yet,
while small differences existed between anemic and
nonanemic subjects in baseline renal function that may
help to explain the presence and severity of anemia be-
tween groups, there were no significant differences in rel-
evant patient characteristics, comorbidities, or other rel-
evant therapies at baseline or during follow-up. While
our study did not address the effects of rhEPO on clini-
cal cardiovascular events or functional status (e.g., New
York Heart Association Class for heart failure symp-
toms), LVH is well-established as a potent risk factor for
cardiovascular death in patients with renal disease [14].
Finally, our study was also unable to determine the spe-
cific reasons for the beneficial effect observed with receipt
of rhEPO therapy in the setting of advanced chronic renal
insufficiency and anemia.
CONCLUSION
LVH is a common complication in chronic renal insuf-
ficiency, and lower hemoglobin level is associated with an
increased risk of LVH. Short-term treatment with rhEPO
in patients with severe chronic renal insufficiency compli-
cated by anemia and LVH was associated with a reduction
in LVMI. Our results are in agreement with and extend
previous studies on the effects of EPO [27, 28]. The mag-
nitude of change in LVMI obtained in our study, if sus-
tained, could lead to the reversal of LVH in mild cases
and may have a demonstrable impact on cardiac mortal-
ity if it can be achieved in a large at-risk population such
as those with chronic renal insufficiency. Indeed, a recent
study by Khan et al [48] shows that pre-ESRD treatment
with EPO is associated with decreased mortality on dial-
ysis. Given the potential implications of our findings to
the growing chronic renal insufficiency population, future
randomized trials of the effect of treating to different tar-
get hemoglobin levels with rhEPO on cardiovascular and
other relevant outcomes in patients with chronic renal in-
sufficiency and LVH are needed.
Appendix. Members of the Spanish Group for the Study of Left
Ventricular Hypertrophy in Pre-dialysis Patients
Hospital Members
H. Universitario Gregorio
Marao`uˆn
Fernando Valderrabano, Jose´ Lun˜o,
and Soledad Garcı´a de Vinuesa
H. Universitario de
Canarias
Vı´ctor Lorenzo, Margarita Rufino
Delgado, Fundaciuˆn Jime´nez Dı´az,
Bele´n Marruˆn, and Carlos
Caramelo Dı´az
H. La Paz Jose´ Luis Miguel Alonso
H. Clı´nico San Carlos Francisco Coronel and Jose Antonio
Herrero
H. Son Dureta Antonio Morey and Rosario
Bernabeu
H. Lluı´s Alcanyı´s Juan Carlos Alonso and Florencio
Sigenza
H. Josep Trueta Martı´ Valle¨s Prats and Josep Maria
Bronsoms
H. General Albacete Jose´ Portole´s
H. General Asturias Julio Herrera and Pedro Vidau
H. Candelaria Jesus Chaı´n and Fernando Moujir
H. Bellvitge Alberto Martı´nez Castelao and
Francesc Moreso
H. Teruel Juan Jose´ Bellvis and Antonio Gascuˆn
H. del Aire Emilio Gonza´lez Parra and Miguel
Rodeles del Pozo
H. Torrecardenas Maria Dolores del Pino
H. Princesa de Espao´a Francisco Fernandez
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